German biotech firm BioNTech (22UAy.DE), has agreed to acquire domestic peer CureVac, for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.
Under the deal, which pairs two former rivals in the race to develop COVID-19 vaccines, CureVac shareholders stand to receive a premium of 55% over the three-month average share price, and leave them with a stake of about 4%-6% in BioNTech, the suitor said.
CureVac's Frankfurt-listed shares surged 27% to a five-month high, valuing the company at €1.04 billion ($1.2 billion), while BioNTech shares were down 2%.
The deal further underscores BioNTech's long-term pursuit of new cancer treatments as it aims to show that its success as Pfizer's COVID-19 vaccine partner, which left its balance sheet flush with billions of euros in cash, was not a fluke.
"With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy," the company said.
CureVac opted to focus on oncology about a year ago when it agreed to sell its remaining influenza and COVID-19 vaccine development to alliance partner GSK.
It had previously cut jobs as it sought to move beyond its failure to develop an mRNA-based COVID vaccine during the pandemic.
GERMAN BIOTECH CHAMPION
The agreement is also set to end CureVac's years-long legal fight over alleged mRNA patent infringement by BioNTech and for a share of vaccine revenues, where CureVac has made little progress.
CureVac shares were worth as much as €120 in December 2020 on hopes it would develop a COVID vaccine, more than double their initial public offer value in August of that year. They are now trading at €4.65.
BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers Squibb agreed to pay up to $11.1 billion to jointly develop a next-generation cancer immunotherapy that could take on rival Merck & Co's best-selling drug Keytruda.
Each CureVac share will be exchanged for about $5.46 in BioNTech American depositary shares, or ADS, but subject to a so-called collar mechanism, BioNTech said.
If the 10-day volume-weighted average price of BioNTech ADS shortly before the closing of the offer exceeds $126.55, the exchange ratio would be 0.04318, and if the price is lower than $84.37, the exchange ratio would be 0.06476.
BioNTech said the deal was supported by SAP SE co-founder and football investor Dietmar Hopp, who holds a stake of about 37% in CureVac.
The German government, owner of about 13% in CureVac for its financial backing during the pandemic, said it welcomed in principle the creation of a "new German biotech champion", and that it would review the offer.
Iran is not seeking war but will only accept a settlement that ensures a permanent end to the conflict, Foreign Minister Abbas Araghchi...
Taiwan Defence Minister Wellington Koo on Thursday says the next arms sale package from the United States is on...
The United Nations has adopted a resolution to recognise transatlantic slavery as the "gravest crime aga...
Foreign ministers from the world's leading Western democracies meet in France this week against the backdro...
Iran is reviewing a U.S. proposal to end the war in the Gulf but has no intention of holding talks to ...
The United States officially left the World Health Organization on 22 January, triggering a financial and operational crisis at the United Nations health agency. The move follows a year of warnings from global health experts that a U.S. exit could undermine public health at home and abroad.
The World Health Organization (WHO) has warned that Afghanistan is facing a worsening humanitarian and health crisis in 2025, with millions of returning refugees expected to stretch the country’s already fragile health system.
Qantas Airways has been fined A$90 million ($58.64 million) for illegally firing 1,800 ground staff during the COVID-19 pandemic and replacing them with contractors, the Federal Court of Australia said on Monday (August 18).
The COVID-19 pandemic exposed deep flaws in how the world prepares for and responds to global health threats. From overwhelmed hospitals to fragmented international coordination, the crisis revealed that preparedness goes beyond stockpiles. It requires trust, transparency, and global cooperation.
Both the United States and Iran are giving conflicting messages about trying to end the conflict in the Middle East as the rest of the world battle with the consequences of the war. Welcome to AnewZ's coverage of the tensions in the Middle East.
Afghan authorities say Pakistani jets entered northern Afghanistan, while Pakistan insists its actions target terrorism, highlighting continued strain after a temporary Eid ceasefire ended.
Danish Prime Minister Mette Frederiksen resigned on Wednesday after her coalition suffered a heavy election defeat, triggering negotiations over who will form the next government.
Iran launched multiple waves of missiles at Israel, the Israeli military said, after U.S. President Donald Trump postponed a threat to bomb the Islamic Republic's power grid because of what he described as productive talks with Iranian officials.
The Iranian Foreign Minister Abbas Araghchi has stated Tehran’s stand on the latest developments in the Israel and the United States war in Iran following U.S. President Donald Trump’s announcement to postpone bombing the country's energy infrastructure.
The UK Health Security Agency (UKHSA) said that as of Wednesday evening, it has identified six new cases of meningococcal disease in Kent, bringing the total of confirmed or suspected cases to at least 27.
The Scottish Parliament has voted against legalising assisted dying, ending a years-long campaign to make Scotland the first part of the UK to allow the practice.
The war in the Middle East is beginning to disrupt the flow of critical medicines to Gulf countries, raising concerns about the supply of cancer treatments and other temperature-sensitive drugs, according to pharmaceutical industry executives.
The World Health Organization (WHO) has released $2m in emergency funding to support health responses in Lebanon, Iraq and Syria as escalating regional conflict strains hospitals, raises displacement and increases pressure on already fragile health systems.
Measles cases across Europe and Central Asia fell sharply in 2025 compared to the previous year but health officials have warned that the risk of fresh outbreaks remains unless vaccination gaps are urgently addressed.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment